



# Biotech Daily

Tuesday March 10, 2015

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH EVEN: ATCOR UP 64%, PHARMAXIS DOWN 10%**
- \* **ATCOR JUMPS 116% ON AMA 'SPHYGMOCOR' CPT CATEGORY 1 CODE**
- \* **FEDERAL SCIENCE MINISTER OPENS FLINDERS TONSLEY CAMPUS**
- \* **ANTEO APPOINTS VERITAS JAPAN MIX&GO DISTRIBUTOR**
- \* **BPH SHARE PLAN RAISES \$204k**
- \* **AVITA REQUESTS 'EQUITY PLACEMENT' TRADING HALT**
- \* **MEDICAL DEVELOPMENTS PLEADS SCHULTZ, NEWS TO ASX 8% QUERY**
- \* **ALLAN GRAY REDUCES TO 17% OF ACRUX**
- \* **ALLAN GRAY REDUCES TO 12% OF QRX**

## MARKET REPORT

The Australian stock market edged up 0.05 percent on Tuesday March 10, 2015 with the S&P ASX 200 up 2.9 points to 5,824.2 points. Fourteen of the Biotech Daily Top 40 stocks were up, 15 fell, 10 traded unchanged and one was untraded. All three Big Caps were up.

Atcor was the best for the second day in a row, climbing as much as 14.5 cents or 116.0 percent to 27.0 cents before closing up eight cents or 64.0 percent to 20.5 cents with 14.4 million shares traded, followed by Compumedics up 12.5 percent to 13.5 cents with 18,000 shares traded.

Clinuvel climbed 9.0 percent; Anteo rose 8.9 percent; Sirtex was up 4.5 percent; Antisense, IDT and Universal Biosensors were up more than three percent; Cellmid and Starpharma rose more than two percent; Cochlear, CSL, Nanosonics, Psivida and Resmed were up more than one percent; with Medical Developments and Mesoblast up by less than one percent.

Pharmaxis led the falls, down 0.85 cents or 9.6 percent to 8.0 cents with 1.1 million shares traded, followed by Analytica down 9.5 percent to 1.9 cents with 3.6 million shares traded.

Circadian, Prima and Tissue Therapies lost more than five percent; Ellex fell 4.4 percent; Acrux, GI Dynamics and Phosphagenics were down three percent or more; Neuren and Viralytics shed two percent or more; Admedus and Alchemia were down more than one percent; with Bionomics and Impedimed down by less than one percent.

## ATCOR MEDICAL

Atcor jumped 116 percent on the American Medical Association recommendation of a current procedural terminology (CPT) category 1 code for arterial pressure waveforms. Atcor said the US Renal Physician Association application for the addition of the category 1 CPT code 9300X1, and deletion of the existing category III code 0311T for non-invasive calculation and analysis of central arterial pressure waveforms with interpretation and report, which included the Sphygmocor central aortic blood pressure waveform measure. The company said that category 1 CPT codes were reserved for those procedures that demonstrated clinical efficacy, were performed by many physicians or other qualified health care professionals across the United States and had US Food and Drug Administration clearance.

Atcor chief executive officer Duncan Ross said that it was "a seminal event in Atcor Medical's history".

"Building a clinical business in the world's largest medical device market has been a cornerstone of Atcor Medical's investment strategy since our [initial public offer] in 2005," Mr Ross said.

"This addition marks a significant step toward more widespread clinical adoption and greater patient access to life-saving technology," Mr Ross said.

"Atcor has built a highly skilled US team with a solid customer base that includes all 17 hospitals on the US News and World Report best hospitals honor roll," Mr Ross said.

"Our company has relationships of trust with key opinion leaders in both research and clinical practice," Mr Ross said.

"Our relationships with key medical societies are well established," Mr Ross said. "Atcor is well positioned to capitalize on increasing customer demand and market access."

Atcor said that current procedural terminology was a listing of descriptive terms and identifying codes for reporting medical services and procedures, intended to provide a standardized language that accurately describes medical, surgical and diagnostic services and serving as an effective means for consistent nationwide communication among physicians and other healthcare providers, patients, and third parties in the US.

The company said that the CPT code was the most widely accepted medical nomenclature used to report medical procedures and services under public and private health programs.

Atcor said that the code was a result of the most recent CPT editorial panel meeting but future panel actions might impact this information and new and revised code descriptions might be refined prior to publication each year.

The company said that code numbers were neither assigned, nor exact wording finalized, until prior to publication of the annual code set and became effective on January 1, 2016, following completion of several further steps.

Atcor said the annual release of the updated CPT codes set coincided with the annual Medicare physician fee schedule and that following the creation of a new CPT category 1 code for central arterial pressure waveforms assessment, the code would be surveyed as part of the AMA and Specialty Society Relative Value Scale Update Committee's review, which makes recommendations to the Centers for Medicare and Medicaid Services on physician work, practice expense inputs and professional liability insurance crosswalks. The company said that these elements contributed to the Medicare fee for the service as well as the basis for commercial insurance contracted rates and the AMA Committee would develop recommendations on the code in April with final fees published in early November 2015.

Atcor climbed as much as 14.5 cents or 116.0 percent to 27.0 cents before closing up eight cents or 64 percent to 20.5 cents with 14.4 million shares traded.

## FEDERAL GOVERNMENT

The Federal Government says Flinders University Tonsley campus integrates teaching, research and entrepreneurship in engineering, medical devices and nanotechnology. A media release from the Federal Industry and Science Minister Ian Macfarlane said he opened the campus today at the site of Mitsubishi Australia's former Tonsley Park car assembly plant.

Mr Macfarlane said the facility was an illustration of both the changing nature of global manufacturing, as well as the opportunities for growth in Australian jobs and industries.

"Australia's industries of the future, like those being developed at Flinders at Tonsley, will be focused on innovation, research and reaching into global market places and global supply chains," Mr Macfarlane said.

"The Australian Government has put science at the centre of industry policy, to assist the transformation of our domestic manufacturing and industry base to bring new focus on areas where Australia has competitive strength," Mr Macfarlane said.

Mr Macfarlane's media release said that Flinders University had invested \$120 million in the Tonsley campus to co-locate its School of Computer Science, Engineering and Mathematics, with its Medical Device Research Institute, Centre for Nanoscale Science and Technology, Flinders' commercialization agent, Flinders Partners and its New Venture Institute which connected the university to businesses and entrepreneurs.

"Co-locating these five entities at Tonsley brings together practical skills with academic expertise and reflects a sustainable future for manufacturing and industry which draws on Australia's world-class science and research through industry-research collaboration," Mr Macfarlane said.

## ANTEO DIAGNOSTICS

Anteo Diagnostics says its Anteo Technologies subsidiary has appointed Japan's Veritas Corp as its exclusive distribution partner for Mix&Go products in Japan.

Anteo said that Veritas distributed products to the in-vitro diagnostics, life sciences research and raw material reagent markets.

The company said that the biological adhesive Mix&Go product range provided "highly functional interfaces between fragile bio-molecules and synthetic, often incompatible materials.

Anteo chief executive officer Dr Geoff Cumming said that Veritas had "a strong and long-standing reputation in Japan for introducing emerging technologies to the Japanese market".

"They are uniquely suited to successfully introduce a new technology such as Anteo's Mix&Go platform," Dr Cumming said.

Anteo was up 0.8 cents or 8.9 percent to 9.8 cents with 7.8 million shares traded.

## BPH ENERGY

BPH says its share purchase plan at 3.935 cents a share was fully subscribed and raised more than \$200,000.

BPH said that under the 30 percent maximum rule applications had been scaled back and an application for listing the 51,768,650 shares would be made, with notifications to shareholders completed within the next two days.

BPH was untraded at 0.5 cents.

### AVITA MEDICAL

Avita has requested a trading halt pending an announcement regarding “an equity placement”.

Trading will resume on March 12, 2015 or on an earlier announcement.

Avita last traded at 7.7 cents.

### MEDICAL DEVELOPMENTS

Medical Developments has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company’s share price increased 19 cents or 8.1 percent from \$2.35 on March 6 to \$2.54 on March 9, 2015, but did not note an increase in trading volumes.

Medical Developments chairman David Williams told Biotech Daily that “the main value drivers for the company previously announced” included the potential registration of Pentrox in the UK and elsewhere in Europe, the potential signing of other distribution deals following the UK agreement with Galen and the beginning of sales of the company’s asthma inhalers in North America.

Medical Developments was up one cent or 0.4 percent to \$2.46.

### ACRUX

Allan Gray Australia has reduced its substantial holding in Acrux from 30,894,080 shares (18.55%) to 27,810,861 shares (16.70%).

Allan Gray said that between May 1, 2014 and March 6, 2015 it bought and sold shares, with the single largest sale 1,676,574 shares between August 21 and November 28, 2014 for \$3,372,149 or \$2.01 a share.

Acrux fell 2.5 cents or three percent to 81.5 cents.

### QRX PHARMA

Allan Gray Australia says it has reduced its substantial holding in QRX, from 20,903,390 shares (13.29%) to 19,746,950 shares (12.03%).

Allan Gray said it sold 1,166,672 shares on March 6, 2015 for \$19,833 or an average price of 1.7 cents a share.

In 2013, QRX raised \$7.5 million through the issue of shares at 60 cents a share and Allan Gray said that between July 10 and November 13, 2013, it bought 3,219,721 shares for \$2,224,673 or an average price of 69.1 cents a share (BD: Nov 13, 19, 2013).

QRX fell 0.1 cents or 5.9 percent to 1.6 cents.